Rough Quarter for Elevance but Brighter Days Ahead with Carelon!
Q2 2024 Earnings
Pretty strong earnings for Elevance with 12% growth in EPS but revenue shrunk 200 million to 43.2 billion. Wall Street did not love the earnings as the stock is down 10% with the increased operating expense as they try to build out Carelon and have faced some timing issues with Medicaid acuity. Most of the questions during the Q&A were focused on how th…
Keep reading with a 7-day free trial
Subscribe to The Healthcare Economy to keep reading this post and get 7 days of free access to the full post archives.